59 results
Page 2 of 3
6-K
EX-99.3
r31bal53yqvdwe0rd
10 Aug 23
Report of Foreign Private Issuer
8:00am
6-K
EX-99.2
9n1 8e2yzf
10 Aug 23
Report of Foreign Private Issuer
8:00am
424B5
inkap
12 Jul 23
Prospectus supplement for primary offering
12:00am
F-3
EX-4.3
c9292m
30 Jun 23
Shelf registration (foreign)
4:06pm
F-3
3gt61hxc
30 Jun 23
Shelf registration (foreign)
4:06pm
6-K
EX-99.1
wft4yej0ob
28 Jun 23
InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer
8:30am
6-K
EX-99.1
71pi9dxyw0xzoeg
21 Jun 23
InflaRx Announces Commercial Launch of Gohibic (vilobelimab) in the U.S. for the Treatment of Critically Ill COVID-19 Patients
8:30am
6-K
EX-99.3
pevup0rd 4f6
11 May 23
Current report (foreign)
8:00am
6-K
EX-99.2
te44hnv0y0 hu50pp4
11 May 23
Current report (foreign)
8:00am
6-K
EX-1.1
0oz3mdz t4qcah
13 Apr 23
Current report (foreign)
4:01pm
424B5
v7ho c3as
13 Apr 23
Prospectus supplement for primary offering
8:48am
424B5
x0kw7nompfwgmmye
11 Apr 23
Prospectus supplement for primary offering
4:11pm
6-K
EX-99.2
upgslz4b iwn
9 Nov 22
Current report (foreign)
7:52am
6-K
EX-99.1
52qnoiyrq b0dy76d
5 Aug 22
Current report (foreign)
6:07am
6-K
EX-99.2
ow65eah
5 Aug 22
Current report (foreign)
6:07am
6-K
EX-99.2
yjwswnm
12 May 22
Current report (foreign)
8:30am
6-K
EX-99.1
137y0 kq3
24 Mar 22
InflaRx Reports Full Year 2021 Financial and Operating Results
8:40am
6-K
EX-99.2
gqm0d96n9s2r mdwle
5 Nov 21
Current report (foreign)
7:30am